Western History Collection
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ou.edu
Clinical Trials
399
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (332 trials with phase data)• Click on a phase to view related trials
Dietary Fiber and Time Restricted Eating
- Conditions
- Diet HabitsCancer Prevention
- First Posted Date
- 2025-10-22
- Last Posted Date
- 2025-10-24
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 90
- Registration Number
- NCT07219706
- Locations
- 🇺🇸
University of Oklahoma Health Sciences, Columbus, Ohio, United States
Program in Oncology for Tribal Health Systems.
- Conditions
- Patient Outcomes
- First Posted Date
- 2025-10-16
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 187
- Registration Number
- NCT07217574
- Locations
- 🇺🇸
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults
- Conditions
- CognitionBrain AgingNeurovascular Coupling Mechanism and Cognitive FunctionNeurovascular ControlBrain Activity
- First Posted Date
- 2025-10-07
- Last Posted Date
- 2025-10-07
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 30
- Registration Number
- NCT07209683
- Locations
- 🇺🇸
University of Oklahoma Health Campus, Oklahoma City, Oklahoma, United States
Meloxicam in Mohs Micrographic Surgery
- Conditions
- Postoperative Pain, AcuteSkin Cancer
- Interventions
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 300
- Registration Number
- NCT07200544
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Circulating Tumor DNA Response In Urothelial Cancer
- Conditions
- Urothelial Carcinoma
- Interventions
- Drug: Pembrolizumab & Enfortumab Vedotin (PEV)
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 30
- Registration Number
- NCT07183319
- Locations
- 🇺🇸
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 80
- Next
News
University of Oklahoma Researchers Unlock Amylin Receptor Mechanisms for Next-Generation Obesity Drugs
University of Oklahoma researchers published breakthrough findings in Science Signaling revealing new understanding of how amylin receptors function, providing crucial insights for obesity drug development.
Smart-T Smoking Cessation App Shows Nearly Double Quit Rates in Low-Income Adults
University of Oklahoma researchers developed Smart-T, a real-time adaptive smartphone app that nearly doubled smoking cessation rates compared to a static app in a clinical trial of 454 low-income smokers.
Novel Hafnium-Based Treatment Trial Launches for Cisplatin-Ineligible Head and Neck Cancer Patients
International researchers launch NANORAY-312 trial investigating hafnium metal therapy combined with radiation as a novel treatment approach for head and neck cancer patients unsuitable for cisplatin treatment.